Supplementary Figure 1: Flow chart for the study.
Inclusion of patients

EuroSIDA
N=18,786
N=14,515
Prospective Follow Up >1/1/05
N=12,279
Eligible for analyses

Exclusions
789 with no platelet counts
29 gender missing, aged <16
1,173 no CD4/ HIV RNA within 6/12 months of baseline
247 no prospective follow up

735 (6.0%) developed AIDS-defining events
1,168 (9.5%) developed non AIDS-defining events
306 (26.2%) developed cardiovascular disease
597 (51.1%) developed non AIDS cancer

Compared to the 12,279 included in analyses, the 2,236 excluded with follow up > 1/1/05 were more likely to be of non-white ethnic origin, be intravenous drug users compared to MSM, be from Eastern Europe compared to Southern Europe, be hepatitis B and C coinfected, antiretroviral therapy naïve, have a later date of enrolment in EuroSIDA and more likely to have a detectable HIV RNA at baseline. Excluded patients were less likely to be from Central and Northern Europe compared to Southern Europe.
Supplementary Figure 2: Distribution of specific non AIDS-defining cancers by current platelet count. HL: Hodgkin lymphoma TERM: terminal disseminated carcinoma of unknown primary site
Distribution of specific non AIDS-defining cancers by current platelet count

<table>
<thead>
<tr>
<th>Current platelet count (x10^9/L)</th>
<th>N</th>
<th>Percentage of cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;=100</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>100-200</td>
<td>209</td>
<td></td>
</tr>
<tr>
<td>200-300</td>
<td>214</td>
<td></td>
</tr>
<tr>
<td>&gt;300</td>
<td>109</td>
<td></td>
</tr>
</tbody>
</table>